Daiichi Sankyo

Daiichi Sankyo stands as a prominent player in the realm of pharmaceuticals and biotechnology, driven by a commitment to innovation and excellence. Established in 2007, the company has been at the forefront of developing groundbreaking treatments and therapies to enhance patient outcomes globally. With a robust research and development framework, Daiichi Sankyo continues to push the boundaries of medical science.

Headquartered in Tokyo, Japan, the company employs a dedicated workforce of approximately 17,000 individuals. These employees are spread across various regions, working collaboratively to advance the company's mission of delivering innovative solutions in healthcare. The leadership under CEO Sunao Manabe has been pivotal in steering the company towards achieving significant milestones in drug discovery and development.

Daiichi Sankyo's portfolio includes a strong focus on oncology and cardiovascular therapies, addressing some of the most pressing health challenges worldwide. The company's strategic initiatives are designed to not only meet current healthcare needs but also anticipate future demands, ensuring a sustainable and impactful presence in the industry. With a steadfast commitment to patient-centricity and quality, Daiichi Sankyo continues to make a significant impact in the field of medicine.